Studies have found that the expression of BTG2 is decreased in various tumor tissues such as prostate cancer, renal cell carcinoma and HCC [7–9], and it has been confirmed to be associated with poor prognosis of breast cancer, bladder cancer and lung cancer [10–12]. Here, BTG2 is linked to urinary bladder carcinoma.